




RealRate

PHARMACEUTICAL 2022

Organogenesis Holdings Inc
Rank 228 of 471

Organogenesis
Empowering Healing



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Organogenesis Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Organogenesis Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 298%, being 23% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	226,979
Cost of Goods Sold	114,199
Intangible Assets	54,445
Liabilities, Current	82,005
Liabilities, Non-Current	48,450
Other Assets	82,675
Other Compr. Net Income	0
Other Expenses	-31,116
Other Liabilities	70,769
Other Net Income	-9,132
Other Revenues	468,059
Property and Equipment	79,160
Research and Development	30,742
Selling, General and Administrative Expense	250,200

Output Variable	Value in 1000 USD
Assets	443,259
Liabilities	201,224
Expenses	364,025
Revenues	468,059
Stockholders Equity	242,035
Net Income	94,902
Comprehensive Net Income	94,902
BaseVar	742,850
ECR before Limited Liability	193%
Economic Capital Ratio	298%